|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.70|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
AstraZeneca topped profit views, but shares crashed on an immuno-oncology setback. Roche also beat.
Roche sees 'mid-single' digit sales growth in second half.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.